Literature DB >> 7125074

Adenocarcinoma of salivary origin. Clinicopathologic study of 204 patients.

R H Spiro, A G Huvos, E W Strong.   

Abstract

We have reviewed a 30 year experience with 204 patients treated for adenocarcinomas of salivary origin. Seventy-one percent had histologically typical adenocarcinomas, whereas 12 percent had papillary, 12 percent mucinous, and 5 percent other unusual variants. Despite these morphologic differences, almost all of the lesions could be classified into one of three histologic grades. The tumors arose most often in the minor salivary glands (138 patients, 68 percent) and the less common variants of adenocarcinoma usually involved the oral cavity, nasal cavity, or paranasal sinuses. High-grade tumors were more often high stage at the time of diagnosis. Treatment almost always consisted of surgical resection which was tailored according to the site and extent of the lesion. Five, 10, and 15 year cure rates were 41, 34, and 28 percent, respectively, and salvage was determined by the grade and stage of the tumor rather than by the extent of the surgery. Local recurrence of this most lethal of salivary tumors exceeded 50 percent. Postoperative teletherapy is probably indicated in most patients if survival rates are to increase, but the role of systemic chemotherapy remains to be defined.

Entities:  

Mesh:

Year:  1982        PMID: 7125074     DOI: 10.1016/0002-9610(82)90416-0

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  13 in total

1.  What Is New in the World Health Organization 2017 Histopathology Classification?

Authors:  Adel K El-Naggar
Journal:  Curr Treat Options Oncol       Date:  2017-07

2.  Coexpression of p53 and c-erbB-2 proteins is associated with histological type, tumour stage, and cell proliferation in malignant salivary gland tumours.

Authors:  N Kamio
Journal:  Virchows Arch       Date:  1996-05       Impact factor: 4.064

3.  Intraoral Pigmented Low-Grade Adenocarcinoma, Not Otherwise Specified: Case Report and Immunohistochemical Study.

Authors:  Jessica Luana Dos Santos; Albina Messias de Almeida Milani Altemani; Alexandre Elias Trivellato; Cássio Edvard Sverzut; Luciana Yamamoto Almeida; Lucas Ribeiro Teixeira; Alfredo Ribeiro-Silva; Jorge Esquiche León
Journal:  Head Neck Pathol       Date:  2017-12-22

4.  Mucus-producing adenopapillary carcinoma of minor salivary gland origin with signet ring cells and intracytoplasmic lumina. A light and electron microscopic study.

Authors:  V C de Araújo; S O de Sousa; E A Lopes; N S de Araújo; A Sesso
Journal:  Arch Otorhinolaryngol       Date:  1988

5.  Prognostic factors associated with decreased survival in patients with acinic cell carcinoma.

Authors:  David M Neskey; Jonah D Klein; Stephanie Hicks; Adam S Garden; Diana M Bell; Adel K El-Naggar; Merrill S Kies; Randal S Weber; Michael E Kupferman
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2013-11       Impact factor: 6.223

6.  Carcinoma of the major salivary glands.

Authors:  S E Afify; J D Maynard
Journal:  Ann R Coll Surg Engl       Date:  1992-05       Impact factor: 1.891

7.  Preinvasive intraductal neoplasia in salivary adenocarcinoma, not otherwise specified.

Authors:  Stephan Ihrler; Andrea Sendelhofert; Christoph Weiler; Hjalmar Hagedorn; John D Harrison
Journal:  Virchows Arch       Date:  2006-05-04       Impact factor: 4.064

8.  Prognosis of salivary adenocarcinomas. A retrospective study of 52 cases with special regard to cytochemically assessed nuclear DNA content.

Authors:  K Hamper; M Brügmann; J Caselitz; H Arps; J Berger; U Askensten; G Auer; G Seifert
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

9.  Long-term effects of parotidectomy.

Authors:  Bektaş Veli Kaya; Caner Kılıç; Samet Özlügedik; Ümit Tuncel; Ela Cömert
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-06-30       Impact factor: 2.503

10.  Clinical approach and treatment of benign and malignant parotid masses, personal experience.

Authors:  F Bussu; C Parrilla; D Rizzo; G Almadori; G Paludetti; J Galli
Journal:  Acta Otorhinolaryngol Ital       Date:  2011-06       Impact factor: 2.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.